Ginsenosides and gut microbiota: differential effects on healthy individuals and irritable bowel syndrome subtypes
Authors:
Open Access
Abstract
Background: Irritable bowel syndrome (IBS) is a common gastrointestinal disorder with poorly understood mechanisms. Variations in gut microbiota composition are observed in different IBS subtypes. Ginsenosides have shown potential in alleviating IBS symptoms, but their interactions with gut microbiota in different IBS subtypes are not well studied. Methods: In this study, we investigated the effects of ginsenosides on the gut microbiota of both healthy participants and participants suffering from IBS characterized by diarrhea (IBS-D) or constipation (IBS-C), using in vitro fermentation alongside 16S rRNA sequencing and bioinformatics analyses. Results: The analysis demonstrated that there were no statistically significant alterations in α- or β-diversity between the ginsenosides-treated and control groups across all models. However, the microbial composition assessment revealed the presence of 51 shared genera, with notable variations in composition and a significant enrichment of specific taxa. Specifically, the LEfSe analysis revealed that, following ginsenosides treatment, the healthy model groups exhibited significant enrichment of Stenotrophomonas and Achromobacter, while the IBS-D model groups demonstrated significant enrichment of Pseudomonas and Stenotrophomonas. Conclusions: The results elucidate the distinctive microbial signatures associated with ginsenosides treatment across both healthy and IBS-D groups, underscoring the potential therapeutic efficacy of ginsenosides in modulating gut microbiota. This study highlights the necessity for further investigation into targeted microbiome therapies for IBS, which may facilitate the development of more personalized and efficacious treatment strategies for gastrointestinal health.Keywords
Funding Information
- Zhejiang Provincial Natural Science Foundation of China (LYY22H280002, LZ23H030002)
- The State Administration of Traditional Chinese Medicine and the Zhejiang Province jointly build Science and Technology Program (GZY-ZJ-KJ-23030)
- the Key Program of the Independent Design Project of National Clinical Research Center for Child Health (I23I0002)
This publication has 39 references indexed in Scilit:
- Unlocking the power of postbiotics: A revolutionary approach to nutrition for humans and animalsCell Metabolism, 2024
- Bacterial, short-chain fatty acid and gas profiles of partially hydrolyzed guar gum in vitro fermentation by human fecal microbiotaFood Chemistry, 2023
- The bioaccessibility, bioavailability, bioactivity, and prebiotic effects of phenolic compounds from raw and solid-fermented mulberry leaves during in vitro digestion and colonic fermentationFood Research International, 2023
- Structural, in vitro digestion, and fermentation characteristics of lotus leaf flavonoidsFood Chemistry, 2022
- In vitro fermentation characteristics of the dietary fiber in bamboo (Phyllostachys edulis) shoots and its regulatory effects on the intestinal microbiota and metabolitesFood Chemistry, 2022
- Gut microbiota associations with diet in irritable bowel syndrome and the effect of low FODMAP diet and probioticsClinical Nutrition, 2021
- Effect of chitooligosaccharides on human gut microbiota and antiglycationCarbohydrate Polymers, 2020
- Gut Microbial Dysbiosis in the Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis of Case-Control StudiesJournal of the Academy of Nutrition and Dietetics, 2020
- Role of ginsenosides, the main active components of Panax ginseng , in inflammatory responses and diseasesJournal of Ginseng Research, 2017
- Comparative Analysis of the Rats’ Gut Microbiota Composition in Animals with Different Ginsenosides Metabolizing ActivityJournal of Agricultural and Food Chemistry, 2017